Author

Todd E. Barnhart

University of Wisconsin–MadisonORCID 0000-0002-9981-2150Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 2 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:imaging· 2 Approach:statistical model· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

Charles K. Stone· 2 shared Jonathan W. EngleiD· 2 shared Karly Alex CodyiD· 2 shared Sterling C. JohnsoniD· 2 shared Tobey J. BetthauseriD· 2 shared Alexander K. ConverseiD· 1 shared Amy K. ErbeiD· 1 shared Arika S. FeilsiD· 1 shared

Activity by Year

2018-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersNeuroscience

Charles K. Stone

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BioengineeringBioconjugate ChemistryPeer-reviewedJul 31, 2025

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors

Zachary T. Rosenkrans, Amy K. Erbe, Nathan B. Clemons…·Reinier T. Hernandez

This paper develops a bispecific antibody targeting GD2 and B7-H3 to improve tumor selectivity and reduce toxicity in GD2-positive tumors.

8 citations

mouseproteomics

𝕏 PostBluesky

NeuroscienceAlzheimer s & Dementia Diagnosis Assessment & Disease MonitoringPeer-reviewedJan 1, 2020

Amyloid duration is associated with preclinical cognitive decline and tau PET

Rebecca L. Koscik, Tobey J. Betthauser, Erin McMullen Jonaitis…·Sterling C. Johnson

This study uses longitudinal amyloid PET data to estimate amyloid chronicity and finds it is linked to cognitive decline and tau burden in preclinical Alzheimer's disease.

104 citationstop 1%

𝕏 PostBluesky

NeuroscienceJournal of Nuclear MedicinePeer-reviewedMay 18, 2018

In vivo characterization and quantification of neurofibrillary tau PET radioligand 18F-MK-6240 in humans from Alzheimer’s disease dementia to young controls

Tobey J. Betthauser, Karly Alex Cody, Matthew D. Zammit…·Bradley Christian

This paper evaluates the in vivo kinetics and quantification of the tau PET radioligand [18F]MK-6240 in humans across Alzheimer’s disease stages and controls.

258 citationstop 1%

𝕏 PostBluesky